Biotechnological innovations in the pharmaceutical industry in Poland 2009 : Market Research Report

Biotechnological innovations in the pharmaceutical industry in Poland 2009

Published by: PMR Ltd.

Published: Aug. 4, 2009 - 85 Pages

Report methodology
Executive summary
Overview of the Polish market of pharmaceutical biotechnology: Key events and trends in the biotechnology sector in Poland; Key trends and events in 2007-2009; Events and trends anticipated for 2009-2011; Key characteristics of the Polish market of biotechnology in pharmaceutics; Value of the Polish market of pharmaceutical biotechnology 2003-2011
Biotech firms in Poland: Foreign investment on the Polish pharmaceutical biotechnology market; Number and classification of Polish biotech firms; Overview of the largest biotech firms on the Polish pharmaceutical market; Biotech companies connected with the pharmaceutical industry
Selected biotechnological innovations of the Polish pharmaceutical industry: Stem cell therapy: Celther; siRNA-based innovative biotech drug: Celon Pharna; Modified monoclonal antibody therapy: Mabion; Tissue engineering and regenerative medicine: Euroimplant; Innovative vaccines against skin and kidney cancer: Biocontract; Innovative platform for the development of biotech drugs: Adamed; Innovation at the point of contact between science and industry: Biotechnology and Antibiotics Institute; Biotech innovations leading to the development of new pharmaceutical substances; Advanced molecular diagnostics for clinical trials: Read-Gene; New technologies for the development of biotech drugs: BioCentrum; Innovative screening and comparative research to find bioactive compounds: Proteon Pharmaceuticals; BioIT as support for the development of innovative drugs: Selvita
Factors material to the development of biotechnology in Poland: Human resources; Opinions about biotechnology in medicine; Legislative environment; Key regulations; Act on genetically modified organisms; Patent law; Legislative support for innovation; Quality standards in the Polish biotech sector; Initiatives supporting the development of innovation and technology transfer; Science & technology and industrial parks; General overview; Current tenants from biotechnology in pharmaceutics and related fields in selected technology parks in Poland; Clusters; EU funding for the development of biotechnology innovations; Access to higher risk capital; List of graphs; List of tables; About PMR; Contact PMR
List of graphs: Value (PLN m) and y-o-y growth of the Polish market of pharmaceutical biotechnology, 2003-2011 12,; Bioton’s revenues (PLN m) and revenue y-o-y change, 2003-2008; Bioton’s net financial result (PLN m), 2003-2008; Bioton’s revenues and net financial result (PLN m), Q1 2008 and Q1 2009; IBSS Biomed’s revenues (PLN m) and y-o-y revenue change in Poland, 1998-2007; IBSS Biomed’s net profit (PLN m) and net profit y-o-y change in Poland, 1998-2007; Biomed Lublin’s revenues (PLN m) and revenue y-o-y change in Poland, 1998-2008; Biomed Lublin’s net financial result (PLN m) in Poland, 1998-2008; Polfa Tarchomin’s sales value structure, 2007; Polfa Tarchomin’s domestic sales value structure, 2008; Polfa Tarchomin’s revenues (PLN m) and revenue y-o-y change, 1998-Q1 2009; Polfa Tarchomin’s net financial result (PLN m), 1998-Q1 2009; Percentage shareholdings in Mabion of Poland, 2009; Euroimplant’s net financial result (PLN’000) in Poland, 2007-2008; Biocontract’s financial results (PLN m) in Poland, 2007; Adamed’s revenues (PLN m) and revenue y-o-y change in Poland, 1999-2008; Adamed’s net financial result (PLN m), 1999-2008; Read-Gene’s net financial result (PLN’000) in Poland, 2005-2009; Forecast for Read-Gene’s revenue and net profit structure in Poland, 2009; BioCentrum’s revenues (PLN m) and revenue y-o-y change in Poland, 2004-2007; BioCentrum’s net profit (PLN’000) and net profit y-o-y change in Poland, 2004-2007; Number of candidates to biotechnology and biomedical engineering specialisation in Poland, 2006-2008; Projected demand for graduates of natural science specialisations in next 5 and 15 years (number of selections of Voivod Labour Offices) in Poland, December 2008; Assessment of results of use of modern biotechnological methods in Poland; Poles’ opinion on use of biotechnology to produce new drugs and vaccines; Opinions on the statement “research into drugs and vaccines to be used in biotechnology and genetic engineering comprise a threat to the environment or human life”; Applications for closed use of GMOs in projects with applications in medicine and pharmaceutics in Poland, 2002-H1 2009; Number of applications for closed GMO use by biotech firms of the pharmaceutical industry in Poland, 2002-H1 2009; List of tables; Structure of Bioton Capital Group, 2008; The most important science and technology parks which have as a priority direction the support of the development of biotechnological companies in Poland, 2009; Selected biotechnology-related cluster initiatives relevant to the pharmaceutical and related industries in Poland, 2009; Companies and institutions from the biopharmaceutical and related sectors, which have received financing from the Innovative Economy Operational Programme and project value in Poland, 2009; List of graphs; Value (PLN m) and y-o-y growth of the Polish market of pharmaceutical biotechnology, 2003-2011 12,; Bioton’s revenues (PLN m) and revenue y-o-y change, 2003-2008; Bioton’s net financial result (PLN m), 2003-2008; Bioton’s revenues and net financial result (PLN m), Q1 2008 and Q1 2009; IBSS Biomed’s revenues (PLN m) and y-o-y revenue change in Poland, 1998-2007; IBSS Biomed’s net profit (PLN m) and net profit y-o-y change in Poland, 1998-2007; Biomed Lublin’s revenues (PLN m) and revenue y-o-y change in Poland, 1998-2008; Biomed Lublin’s net financial result (PLN m) in Poland, 1998-2008; Polfa Tarchomin’s sales value structure, 2007; Polfa Tarchomin’s domestic sales value structure, 2008; Polfa Tarchomin’s revenues (PLN m) and revenue y-o-y change, 1998-Q1 2009; Polfa Tarchomin’s net financial result (PLN m), 1998-Q1 2009; Percentage shareholdings in Mabion of Poland, 2009; Euroimplant’s net financial result (PLN’000) in Poland, 2007-2008; Biocontract’s financial results (PLN m) in Poland, 2007; Adamed’s revenues (PLN m) and revenue y-o-y change in Poland, 1999-2008; Adamed’s net financial result (PLN m), 1999-2008; Read-Gene’s net financial result (PLN’000) in Poland, 2005-2009; Forecast for Read-Gene’s revenue and net profit structure in Poland, 2009; BioCentrum’s revenues (PLN m) and revenue y-o-y change in Poland, 2004-2007; BioCentrum’s net profit (PLN’000) and net profit y-o-y change in Poland, 2004-2007; Number of candidates to biotechnology and biomedical engineering specialisation in Poland, 2006-2008; Projected demand for graduates of natural science specialisations in next 5 and 15 years (number of selections of Voivod Labour Offices) in Poland, December 2008; Assessment of results of use of modern biotechnological methods in Poland; Poles’ opinion on use of biotechnology to produce new drugs and vaccines; Opinions on the statement “research into drugs and vaccines to be used in biotechnology and genetic engineering comprise a threat to the environment or human life”; Applications for closed use of GMOs in projects with applications in medicine and pharmaceutics in Poland, 2002-H1 2009; Number of applications for closed GMO use by biotech firms of the pharmaceutical industry in Poland, 2002-H1 2009; List of tables; Structure of Bioton Capital Group, 2008; The most important science and technology parks which have as a priority direction the support of the development of biotechnological companies in Poland, 2009; Selected biotechnology-related cluster initiatives relevant to the pharmaceutical and related industries in Poland, 2009; Companies and institutions from the biopharmaceutical and related sectors, which have received financing from the Innovative Economy Operational Programme and project value in Poland, 2009

Abstract

Biotechnological innovations in the pharmaceutical industry in Poland 2009 provides a comprehensive overview of the biotechnology market in Poland. Covering major industry trends and events, it touches on both domestic and international occurrences that have significance to the Polish market. The report also investigates the size of the market and the most important innovations relevant to the pharmaceutical sector in recent years. From an operational point of view, the report profiles the major players active on the Polish market, as well as the legislative setting they face. A directory of the 20 largest biopharmaceutical companies and developmental forecasts up to 2011 is included.

The report also comprises:

the value of biotechnology market Polish pharmaceutical industry
data on niche biotech market segments in Poland
key players on the market profiles
undergoing investments in Poland
legislation briefing regarding biotechnology market in Poland

Biotechnological innovations in the pharmaceutical industry in Poland 2009 was prepared using PMR MarketInsight Methodology.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 30

Biotechnological innovations in the pharmaceutical industry in Poland 2009

Table of Contents

Abstract